We have recently evidenced that the number of tumor-infiltrating NK cells (TI-NK) in diagnostic biopsies was associated to the achievement of pCR and prolonged disease-free survival upon neoadjuvant treatment with anti-HER2 antibodies, independently of conventional clinicopathological factors [7]. Here, ERBB2 is linked to neoplasm.